Amicus’ Pompe disease therapy joins early access scheme
The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease
Read More
Tag: EAMS
Patients gain early access to Pfizer’s atopic dermatitis drug
The MHRA has issued a positive scientific opinion for abrocitinib allowing its use via the early access to medicines scheme (EAMS)
Read More
MHRA allows HAE patients early access to berotralstat
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Read More
UK bladder cancer patients get early access to Bavencio
UK MHRA has issued positive scientific opinion enabling the drug’s inclusion on the Early Access to Medicines Scheme
Read More
UK’s MHRA allows early access to lumasiran for ultra-rare disease
Lumasiran targets primary hyperoxaluria type 1 (PH1), which affects just around 90 people in the UK and one to three individuals per million in Europe
Read More
MHRA extends access to Santhera’s DMD drug via the EAMS
The scientific opinion has been extended for one year while the drug is under regulatory review
Read More
NHS patients to be given experimental coronavirus therapy remdesivir
The drug will be provided to the NHS free of charge by Gilead via the UK’s early access to medicines scheme
Read More
MHRA gives Bavencio, Inlyta combo Early Access to Medicines status
The opinion is for the indication of RCC, the most common kind of kidney cancer found in adults.
Read More
MHRA renews EAMS scientific opinion for Puldysa in DMD
The drug has been available in the UK through EAMS since June 2017.
Read More
UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.
Read More
Early access to Tecentriq combination granted through EAMS
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read More
Pfizer’s lorlatinib clears first hurdle to UK early access scheme
Pfizer’s lorlatinib has been designated a Promising Innovative Medicine for the treatment of some patients with ALK-positive advanced non-small cell lung cancer.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
